Skip to main content

Find Clinical Trials

Home
Conditions
Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Clinical trial condition

Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Explore clinical trials studying Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer trial results

Not Yet Recruiting

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

NCT07466303

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +6 more
Locations: the First Affiliated Hospital of the Air Force Medical University Xi'an, China

View Trial Details